AU2016217496B2 - Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide - Google Patents

Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide Download PDF

Info

Publication number
AU2016217496B2
AU2016217496B2 AU2016217496A AU2016217496A AU2016217496B2 AU 2016217496 B2 AU2016217496 B2 AU 2016217496B2 AU 2016217496 A AU2016217496 A AU 2016217496A AU 2016217496 A AU2016217496 A AU 2016217496A AU 2016217496 B2 AU2016217496 B2 AU 2016217496B2
Authority
AU
Australia
Prior art keywords
solvate
crystalline form
compound
crystalline
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016217496A
Other languages
English (en)
Other versions
AU2016217496A1 (en
Inventor
Ann Marie Diederich
Philip Anthony Harris
Robert Herrmann
John Kenna
Lara Kathryn LEISTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2016217496A1 publication Critical patent/AU2016217496A1/en
Application granted granted Critical
Publication of AU2016217496B2 publication Critical patent/AU2016217496B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/04—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016217496A 2015-02-13 2016-02-12 Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide Ceased AU2016217496B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115674P 2015-02-13 2015-02-13
US62/115,674 2015-02-13
PCT/IB2016/050755 WO2016128936A1 (en) 2015-02-13 2016-02-12 Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide

Publications (2)

Publication Number Publication Date
AU2016217496A1 AU2016217496A1 (en) 2017-08-17
AU2016217496B2 true AU2016217496B2 (en) 2019-03-07

Family

ID=55359562

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016217496A Ceased AU2016217496B2 (en) 2015-02-13 2016-02-12 Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Country Status (11)

Country Link
US (1) US10287280B2 (enExample)
EP (1) EP3256467A1 (enExample)
JP (1) JP2018505199A (enExample)
KR (1) KR20170117472A (enExample)
CN (1) CN107207485A (enExample)
AU (1) AU2016217496B2 (enExample)
BR (1) BR112017017411A2 (enExample)
CA (1) CA2976172A1 (enExample)
IL (1) IL253731A0 (enExample)
RU (1) RU2017131862A (enExample)
WO (1) WO2016128936A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017069279A1 (ja) 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
WO2019123219A1 (en) * 2017-12-20 2019-06-27 Glaxosmithkline Intellectual Property Development Limited Crystalline salt form of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
PL3788045T3 (pl) 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
US20220218719A1 (en) * 2019-05-17 2022-07-14 Glaxosmithkline Intellectual Property Development Limited Matrix composition comprising (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
ES3043457T3 (en) 2019-09-06 2025-11-25 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
AU2020341708B2 (en) 2019-09-06 2024-01-04 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
SMT202600151T1 (it) 2019-11-07 2026-05-12 Rigel Pharmaceuticals Inc Composti eterociclici inibitori di rip1
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014125444A1 (en) * 2013-02-15 2014-08-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014125444A1 (en) * 2013-02-15 2014-08-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BYRN S ET AL, "PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, (1995-07-01), vol. 12, no. 7, doi:10.1023/A:1016241927429, ISSN 0724-8741, pages 945 - 954 *
CAIRA, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (1998-01-01), vol. 198, ISSN 0340-1022, pages 163 - 208 *

Also Published As

Publication number Publication date
RU2017131862A (ru) 2019-03-13
WO2016128936A1 (en) 2016-08-18
EP3256467A1 (en) 2017-12-20
CN107207485A (zh) 2017-09-26
US20180022737A1 (en) 2018-01-25
RU2017131862A3 (enExample) 2019-06-06
KR20170117472A (ko) 2017-10-23
BR112017017411A2 (pt) 2018-04-03
CA2976172A1 (en) 2016-08-18
AU2016217496A1 (en) 2017-08-17
US10287280B2 (en) 2019-05-14
IL253731A0 (en) 2017-09-28
JP2018505199A (ja) 2018-02-22

Similar Documents

Publication Publication Date Title
US10287280B2 (en) Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
CA3060121C (en) Polymorphic form of compound, preparation method and use thereof
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
CN105008322B (zh) 白桦脂醇的衍生物
EP3325477B1 (en) Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
CA3013433A1 (en) Sulfonamide derivative and pharmaceutical composition containing same
US20240383919A1 (en) Substituted 3,4,12,12a-Tetrahydro-1H-[1,4]Oxazino[3,4-c]Pyrido[2,1-f][1,2,4]Triazine-6,8-dione, Pharmaceutical Composition, Method for the Production and Use Thereof
US20190389836A1 (en) Nrf2 activator
WO2011134296A1 (zh) （6，7-二氢-2-硝基-5h-咪唑[2，1-b][1，3]噁嗪-6-基）酰胺化合物、其制备方法和用途
EP3914589A1 (en) Methods of treating disease with magl inhibitors
KR101902567B1 (ko) 플루오로치환된 (3r,4r,5s)-5-구아니디노-4-아세트아미도-3-(펜탄-3-일옥시)사이클로헥센-1-카복실릭 엑시드, 이의 에스테르 및 이의 용도
CN118480041A (zh) 取代的多环化合物及其药物组合物和用途
CN104844679B (zh) 白桦脂醇的衍生物
KR20080080125A (ko) 신규 플레우로뮤틸린 유도체 및 그의 용도
WO2019048808A1 (en) NOVEL POLYMORPHS OF DOLUTÉGRAVIR SODIQUE
CA1227802A (en) Derivatives of bicyclic aminoacids, processes for their preparation, agents containing these derivatives and their use as intermediates and processes for their preparation
EP3412677A1 (en) Cyclobutyl (s)-2-[[[(r)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and method for producing and using same
US20230331667A1 (en) Process for making a pharmaceutical compound
JP2006232671A (ja) 新規セレナゾリン誘導体
KR20250103525A (ko) 아다만틴 내성 한계를 극복한 인플루엔자 바이러스 치료제로서의 m2 억제 효능을 지닌 화합물 및 이의 용도
EA044023B1 (ru) Замещенный 3,4,12,12а-тетрагидро-1н-[1,4]оксазино[3,4-c]пиридо[2,1-f][1,2,4]триазин-6,8-дион, фармацевтическая композиция, способы их получения и применения
WO2019123219A1 (en) Crystalline salt form of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
JPH02279673A (ja) キノロン誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired